Investor Relations Home

Profile
IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market.

The Company was incorporated in California in February 1989 as IRIS Medical Instruments, Inc. In November 1995, we changed our name to IRIDEX Corporation and reincorporated in Delaware. Investors and others should note that we announce material financial information to our investors using SEC filings, press releases, our investor relations website, public conference calls and webcasts.  We use these channels as well as social media to communicate with investors, customers and the public about our company, our products and other issues.  It is possible that the information we post on social media channels could be deemed to be material information.  We encourage investors, our customers, and others interested in our company to review the information we post on our Facebook page (www.facebook.com/IRIDEX) and Twitter feed (https://twitter.com/IRIDEX).
Stock Quote
IRIX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$8.81
Change (%)0.00 (0.00%)
Volume6,002
Data as of 12/19/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
11/19/14IRIDEX Secures Large Tender from Government of Zambia for Ophthalmology Laser Equipment
Expanding Tender Activity in Developing Economies Demonstrates Recognition of Low Cost, Durable Therapeutic Advantages of Laser-Based Treatments for Ophthalmologic Diseases MOUNTAIN VIEW, Calif., Nov. 19, 2014 /PRNewswire/ -- IRIDEX Corporation (Nasdaq:IRIX) announced today that it has been awarded a competitive tender for more than $350,000 in ophthalmology laser equipment by the government of Zambia. Will Moore, IRIDEX President and CEO said, "The incidence of diabetes continues to gr... 
Printer Friendly Version
10/30/14IRIDEX Reports 2014 Third Quarter, Nine-Month Results
MOUNTAIN VIEW, Calif., Oct. 30, 2014 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter and nine months ended September 27, 2014.  Revenues were $10.1 million in the third quarter of 2014, a record for the company's third quarter and up 6% from $9.5 million in the 2013 third quarter. Revenues for the first nine months of 2014 were $31.0 million, up 12% from $27.7 million in the first nine months of last year. Gross margin for the quar... 
Printer Friendly Version
10/23/14IRIDEX Announces Third Quarter 2014 Conference Call and Release Date
MOUNTAIN VIEW, Calif., Oct. 23, 2014 /PRNewswire/ -- IRIDEX Corporation (NASDAQ: IRIX) today announced that it will release its third quarter 2014 financial results after the market closes on Thursday, October 30, 2014.  In conjunction with the release, the Company will host a conference call with the investment community at 5:00 p.m. Eastern Time on Thursday, October 30, 2014 to discuss the results of the quarter and other business developments. Interested parties may access the live confe... 
Printer Friendly Version
10/17/14IRIDEX to Host MicroPulse® Worldwide 3-Day Forum at the American Academy of Ophthalmology
Fourteen Physicians, Eight New to the IRIDEX Podium, will Share their Experiences using MicroPulse® Laser Therapy for Retina and Glaucoma MOUNTAIN VIEW, Calif., Oct. 17, 2014 /PRNewswire/ -- IRIDEX Corporation (Nasdaq:IRIX) announced today its Speakers' Forum program at the annual meeting of the American Academy of Ophthalmology to be held on October 18 – 21 at McCormick Place in Chicago. The Forum consists of a comprehensive 3-day schedule of activities at the IRIDEX booth featuring 13 Micro... 
Printer Friendly Version
Primary IR Contact
Jim Mackaness
Chief Financial Officer and Chief Operating Officer
Phone: 650-605-8716
E-mail: jmackaness@iridex.com


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.


logo aa0logo agslogo ascrslogo asrslogo esrs0logo euretina